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Objective: Partial left ventriculectomy has been introduced as an alterna-
tive surgical therapy to heart transplantation. We performed a single-
center, retrospective analysis of all patients with idiopathic dilated car-
diomyopathy who underwent partial left ventriculectomy or heart
transplantation or who were listed for transplantation to determine
operative mortality rate, 12-month survival, freedom from death on the
heart transplantation waiting list, and freedom from death or need for
relisting for heart transplantation. Methods: Patients who had partial left
ventriculectomy (October 1996 to April 1998) were retrospectively com-
pared with patients who were listed for heart transplantation (January
1995 to April 1998). Survival was assessed after the surgical procedure
(partial left ventriculectomy vs heart transplantation) and from time of
listing for heart transplantation to assess the additional impact of wait-
ing list deaths. Freedom from death or relisting for heart transplanta-
tion was also compared. Results: There was no difference in age or United
Network for Organ Sharing status between the 2 groups. Twenty-nine
patients with idiopathic dilated cardiomyopathy were listed for heart
transplantation; 17 patients underwent transplantation, 6 patients died
while on the waiting list, and 6 patients remain listed. One patient died
after heart transplantation, and 1 patient required relisting. Sixteen
patients had partial left ventriculectomy; 10 patients are in improved
condition, 2 patients died (1 death early from sepsis and 1 death from
progressive heart failure), and 4 patients required relisting for heart
transplantation. Operative survival was 94% after partial left ven-
triculectomy and 94% after heart transplantation (P = .92). Post-
operative 12-month Kaplan-Meier survival was 86% after partial left
ventriculectomy and 93% after heart transplantation (P = .90). Twelve-
month Kaplan-Meier survival after listing for heart transplantation was
75% due to death while on the waiting list (P = .76). Freedom from death
or need for relisting for heart transplantation was 56% after partial left
ventriculectomy and 86% after transplantation (P = .063). Conclusion:
Operative and 12-month survival after partial left ventriculectomy and
heart transplantation were comparable. However, despite their initial
improvement, many patients who underwent partial left ventriculectomy
required relisting for transplantation. Although partial left ventriculec-
tomy is associated with acceptable operative and 12-month survival, it
may prove to serve better as a bridge to transplantation in patients with
idiopathic dilated cardiomyopathy rather than definitive therapy, given
the number of patients who required relisting for transplantation.
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O rthotopic heart transplantation (OHT) remains thestandard with which all other alternative surgical
therapies for the treatment of end-stage cardiomy-
opathies are compared. Today with the current prac-
tices of immunosuppression and the use of surveillance
endomyocardial biopsy, survival after OHT is 84% at 1
year and 74.5% at 3 years in the United States.1 Despite
these appealing results, only a small percentage of
patients who could potentially benefit will receive OHT
because of the shortage of donor supply, the strict
selection criteria, and the substantial financial consid-
erations. Recently, partial left ventriculectomy (PLV)
was introduced by R. J. V. Batista, MD, of Curitiba,
Brazil, as an alternative surgical therapy for the treat-
ment of patients with end-stage dilated cardiomyopa-
thy. To date, little is known about the potential benefits
or the long-term results of this procedure. We therefore
performed a single-center, retrospective analysis of all
patients with idiopathic dilated cardiomyopathy
(IDCM) who underwent OHT or PLV to determine
operative mortality rates, 12-month survival, and free-
dom from death or need for relisting for OHT.
Methods
From October 1996 to April 1998, all patients evaluated
with end-stage heart failure as the result of IDCM were con-
sidered potential candidates for PLV. All of these patients
underwent a complete heart transplantation evaluation, which
included exercise oxygen consumption, dobutamine echocar-
diography, and quality of life questionnaire. Patients with
IDCM, left ventricular end-diastolic diameter (LVEDD)
greater than 7 cm, New York Heart Association (NYHA) class
IV symptoms despite maximal medical therapy, and severely
impaired exercise oxygen consumption were considered can-
didates for PLV. Patients were not excluded from PLV on the
basis of right ventricular dysfunction, elevated transpul-
monary gradient, presence of incidental coronary disease,
need for inotropic agents, or an intra-aortic balloon pump.
Patients who met all criteria for both OHT and PLV were
given both options. Patients who did not meet the require-
ments for transplantation were given the option of PLV or
continued maximal medical management. This study was
approved by the Institutional Review Boards of the
University of Louisville and Jewish Hospital, Louisville,
Kentucky. All of the follow-up studies were performed at
Jewish Hospital, Louisville, Kentucky.3
Patients who had PLV were retrospectively compared with
all patients with IDCM who were listed for OHT from
January 1995 to April 1998. Age, gender, United Network for
Organ Sharing (UNOS) status, and death were identified for
all patients. The primary objective was to compare postoper-
ative survival between patients who had PLV or OHT. The
Kaplan-Meier method was used to estimate postoperative sur-
vival for the PLV and OHT groups.2 Log-rank statistics and
Cox regression were used to compare the postoperative PLV
and OHT groups statistically (SAS Institute, Cary NC),
where the initial time (t = 0 days) was defined as the date of
the procedure (PLV or OHT). A secondary objective was to
compare postoperative survival after PLV with survival from
the time of listing for OHT. The Kaplan-Meier method was
used to estimate survival.2 Log-rank statistics and Cox
regression were used to compare the PLV and OHT groups,
where the initial time (t = 0 days) was defined as the date of
the procedure (PLV) and the date of listing for OHT. A third
objective was to compare postoperative survival and freedom
from relisting for OHT between patients who had a PLV or
OHT surgical procedure. The Kaplan-Meier method was
used to estimate postoperative survival and freedom from
relisting rates for the PLV and OHT groups.2 Log-rank statis-
tics and Cox regression were used to compare the postopera-
tive survival and freedom from relisting for OHT for the PLV
and OHT groups, where the initial time (t = 0 days) was
defined as the date of the procedure (PLV or OHT).
Our operative technique for PLV has previously been de-
scribed and is reviewed here for completeness.3 Echo-
cardiographic assessment of LVEDD was determined before
the operation with a transgastric short axis view for assess-
ment of the interpapillary muscle distance to determine
whether resection of the lateral wall between the papillary
muscles would be adequate to decrease the LVEDD to
approximately 6 cm or less. If resection of the interpapillary
muscle would not result in adequate decrease in LVEDD, a
decision was made to proceed with either mitral valve
replacement or mitral valve repair with reimplantation of the
papillary muscle. There were no strict guidelines for deciding
between repair and replacement. However, if we planned to
resect more than 3 cm posterior to the posterior papillary
muscle, mitral valve replacement was performed through the
left ventriculotomy. Tricuspid valve annuloplasty was per-
formed for significant (>2+) regurgitation.
A median sternotomy was performed with standard aortic
and bicaval cannulation, and cardiopulmonary bypass was
initiated. The tricuspid valve was repaired on the beating
heart. For patients who required mitral valve repair, the mitral
valve was exposed through a standard left atriotomy after
arrest of the heart with antegrade and retrograde cardioplegia.
Standard annuloplasty with a Physio ring (Baxter Carpentier-
Edwards; Baxter Health Care Corp, Irvine Calif) was per-
formed by downsizing the ring by 1 or 2 sizes to ensure ade-
quate leaflet coaptation and thereby prevent central
regurgitation. After completion of the mitral valve repair, a
warm dose of cardioplegic solution was given, and the aortic
crossclamp was released. An incision was then made in the
left ventricle to the left of the left anterior descending artery
and 3 cm proximal to the apex. The position of the papillary
muscles was determined, and an incision was extended along
the base of the anterior papillary muscle to within 2 cm of the
atrioventricular groove. The incision was then extended par-
allel to the left anterior descending artery and along the base
of the posterior papillary muscle to complete the resection.
Initially, the ventricle was closed with interrupted 2-0 sutures
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(Ethibond; Ethicon, Inc, Somerville, NJ) and felt strips fol-
lowed by a 1-0 Ethibond running suture. Recently, we have
closed the ventricle with 2 running sutures of 1-0 Vicryl
polyglactin 910 (Ethicon). Aggressive deairing maneuvers
were performed with echocardiographic evaluation for the
presence of intracavitary air. The patients were then weaned
from cardiopulmonary bypass. Postoperative echocardio-
graphic assessment of mitral regurgitation, tricuspid regurgi-
tation, and left ventricular function was performed.3
Results
From October 1996 to April 1998, 16 patients under-
went PLV, with a mean follow-up of 11.1 months.
Mean age was 49.6 ± 10.5 years (range, 30-67 years);
14 patients were male (14 of 16 patients, 88%). All
patients were in NYHA class IV heart failure and mean
preoperative maximal exercise oxygen consumption
was 13.5 ± 3.0 mL oxygen per kilogram per minute.
Six patients (6 of 16 patients, 37%) were UNOS status
I. Fifteen patients had mitral regurgitation with a mean
grade of 3.3 ± 0.7. Thirteen patients had mitral valve
repair, 2 patients had mitral valve replacement, and 1
patient without mitral regurgitation underwent PLV
without a mitral valve procedure. Six patients required
tricuspid valve repair.
Left ventricular ejection fraction improved immedi-
ately after PLV from 13.9 ± 5.6 to 21.0 ± 8.4 (P = .001,
paired t test) and continued to be significantly improved
at the 3-month (19.6 ± 3.6), 6-month (19.7 ± 2.7), and
12-month (20.3 ± 6.2) postoperative follow-up exami-
naations (Fig 1; P = .032, repeated-measures analysis of
variance). LVEDD was significantly reduced after the
operation, from 8.2 ± 1.1 to 6.4 ± 0.8 cm (P = .002,
paired t test), and continued to be significantly reduced
at 3 months (6.4 ± 0.8 cm), 6 months (6.8 ± 0.6 cm), and
12 months (6.7 ± 0.4 cm) after PLV (Fig 2; P = .0001,
repeated-measures analysis of variance). The degree of
mitral regurgitation was significantly decreased from
3.3 ± 0.7 before the operation to 0.1 ± 0.0 after the oper-
ation (P = .0004, paired t test). One patient had mild
(1+) mitral regurgitation immediately after the opera-
tion, and 15 patients had no mitral regurgitation. Mitral
regurgitation did not worsen in any of the patients dur-
ing the 12-month follow-up period. Compared with pre-
operative values, there was a significant improvement in
NYHA class at 3 months (1.7 ± 0.7), 6 months (2.1 ±
1.1), and 12 months (1.6 ± 1.5; Fig 3; P = .043, repeat-
ed-measures analysis of variance).
There was 1 early death from an unknown cause after
PLV on postoperative day 20. This patient had marked
leukocytosis, dyspnea, and hypothermia. He was given
Fig 1. Improvement in left ventricular ejection fraction after
PLV.
Fig 2. Reduction in LVEDD after PLV.
Fig 3. Improvement in NYHA class after PLV.
Table I. Comparison of PLV and OHT demographics
PLV OHT
Patients (n) 16 17
Mean follow-up (mo) 11.1 16.4*
Mean age (y) 49.6 ± 10.5 50.6 ± 1.6†
Male:female (%) 14 (88):2(12) 9 (53):8(47)‡
UNOS status I (%) 6 (37) 7 (41)§
*P = .001. 
†P = .328.
‡P = .031.
§P = .829.
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broad-spectrum antibiotic therapy, but progressive
hypotension and bradycardia developed. All efforts to
resuscitate him were unsuccessful. An autopsy was not
obtained.
Five patients who showed initial improvement in
clinical status and left ventricle function after PLV
experienced worsening heart failure. One of these
patients died at 6 months after PLV as the result of
worsening congestive heart failure and progressive
multisystem organ failure. The other 4 patients
required listing for transplantation on postoperative
days 96, 175, 246, and 348. Two of these patients
required placement of a left ventricular assist device on
postoperative days 246 and 445. One patient placed on
Fig 4. Survival after OHT and PLV.
Fig 5. Survival after listing for OHT compared with survival after PLV.
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a left ventricular assist device has undergone transplan-
tation and is doing well; the other 3 patients are await-
ing transplantation.
From January 1995 to April 1998, 29 patients with
IDCM were listed for OHT. The average length of time
on the waiting list before OHT was 140.2 ± 60.8 days
(range, 3-595 days). Six of the 29 patients (21%) died
while on the waiting list, 6 patients remain on the wait-
Fig 6. Freedom from listing for OHT after PLV.
Fig 7. Freedom from death and relisting for OHT compared with PLV.
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ing list, and 17 patients underwent OHT. The mean age
of the OHT group was 50.6 ± 1.6 years (range, 30-65
years), and there were 9 male patients (9 of 17 patients,
53%) compared with 88% in the PLV group (P = .032).
The mean follow-up time was 16.4 months. Seven of
the 17 patients (41%) were UNOS status I compared
with 37% in the PLV group (P = .829; Table I). One
patient died 10 days after transplantation owing to mul-
tisystem organ failure. One patient was relisted for
OHT as the result of refractory, chronic vascular rejec-
tion with subsequent graft dysfunction.
Operative mortality was 5.9% (1 of 17 patients), and
12-month Kaplan-Meier survival was 93% for OHT,
compared with 6.3% (1 of 16 patients) and 86% for PLV
(Fig 4). There was no significant difference in operative
deaths (P = .97) and 12-month survival (P = .90)
between the PLV and OHT groups. Kaplan-Meier sur-
vival after listing for OHT (ie, after intent to treat) was
75% at 12 months, primarily the result of a 21% mortal-
ity rate while awaiting transplantation, compared with
86% survival after PLV (P = .76; Fig 5). Freedom from
need for relisting for OHT was 73% after PLV compared
with 93% after OHT at 12 months (P = .003; Fig 6). The
Kaplan-Meier estimate of freedom from death or the
need for relisting for OHT after PLV was 65% at 12
months compared with 86% after OHT (P = .063; Fig 7). 
Discussion
PLV was introduced by R. J. V. Batista as an alterna-
tive surgical treatment to improve left ventricular per-
formance and to ameliorate the symptoms of heart fail-
ure in patients with end-stage cardiomyopathy. Batista
and colleagues4 demonstrated that in some instances
this operative approach would result in marked
improvement in left ventricular performance and func-
tional class. Recently, a number of centers have report-
ed prospective trials of PLV with acceptable morbidity
and mortality rates.5-10 However, there have been no
studies to compare the results after PLV with the results
seen after OHT. We therefore retrospectively reviewed
our results after PLV and compared those to our results
seen after OHT.
All patients in the PLV group and the OHT group had
IDCM and met all standard medical criteria for heart
transplantation. There was no significant difference
between the age or UNOS status between the 2 groups;
however, there was a difference in gender, with PLV
being performed on predominantly male patients (88%)
whereas gender in patients having OHT was more
evenly divided (53%).
There was no difference in operative deaths between
the 2 groups (6.3% for the PLV group vs 5.9% for the
OHT group; P = .97). One early death after OHT was
due to allograft dysfunction and multisystem organ
failure. One early death occurred after PLV from pre-
sumed sepsis. There was also no significant difference
in 12-month survival after PLV or OHT (86% vs 93%;
P = .90). However, 5 of the 16 patients who had PLV
experienced worsening heart function. One of these
patients ultimately died of progressive heart failure,
and 4 of these patients have required relisting for trans-
plantation. Two of these patients have required place-
ment of a left ventricular assist device as a bridge to
transplantation. This 31% incidence of worsening heart
failure, with 13% requiring mechanical circulatory
assistance, is consistent with findings published by oth-
ers.9 However, unlike the experience reported by
McCarthy and colleagues,9 our failures have usually
occurred after discharge, with patients being relisted an
average of 226 days after PLV. Conversely, only 1
patient required relisting for transplantation after OHT.
This patient experienced refractory vascular rejection
with subsequent biventricular failure.
Because of the 31% incidence of worsening heart fail-
ure after PLV, the freedom from relisting for heart trans-
plantation at 12 months was 75% after PLV compared
with 94% after OHT. However, when considering the
survival from time of intent to treat (time from listing for
OHT vs time from PLV), the 12-month survival for the
OHT group was 75% due to a waiting list mortality rate
of 21%. This compares with an 86% 12-month survival
after PLV. Therefore the incidence of recurrent conges-
tive heart failure after PLV has to be weighed against the
presence of waiting list deaths in the OHT group.
In summary, the operative and 12-month survivals
after PLV and OHT are comparable. However, despite
their initial improvement, a number of patients who
underwent PLV experienced recurrent heart failure,
which resulted in death or required relisting for trans-
plantation. Treatment with PLV seems to have the
advantage of avoiding the significant risk of death
while the patient is waiting for an appropriate donor
organ. Although PLV is associated with acceptable
operative and 12-month survival, it may prove to serve
better as a bridge to transplantation in patients with
IDCM rather than definitive therapy, given the number
of patients who required relisting for transplantation.
Our current efforts are focused on methods to identify
the patients who are more likely to have a sustained
improvement after PLV. 
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Discussion
Dr Steven Gundry (Loma Linda, Calif). The authors
bring up a series of patients who were all potential trans-
plantation candidates and who were qualified for transplan-
tation, and they have compared these patients with a group
of patients who had a Batista operation instead of the initial
transplantation.
At our institution, we have used a Batista-type operation in
18 patients over the past 2 years. Specifically, we excluded
transplantation candidates from this study. But it is interest-
ing to note that after 24 months, our first 2 patients are still
alive after a PLV. However, our experience overall has been
that approximately one third of the patients will die, one third
of the patients will be unchanged, and one third of the
patients will improve. I notice the authors have come across
very similar statistics, although phrased in a different way.
I have several questions for the authors. First, you have
decided to compare different time periods in your study.
Specifically, you have included an extra year and a half of
looking at potential heart transplantation patients versus only
approximately a year and a half total of Batista patients. Was
there a reason that you went back farther to look at the heart
transplantation candidates as opposed to the Batista patients?
Dr Etoch. Yes, we were trying to identify a very similar
cohort for comparison and to compare the 2 groups from time
of intent to treat. To achieve this we had to include the time
on the waiting list for the heart transplantation group. 
Dr Gundry. There would, of course, be a considerable dif-
ference in your outcome had the waiting list mortality rate for
heart transplantation not been so large; that is, 21% of your
patients on the heart transplantation list died while waiting. I
am curious about the time period that you studied (January 1,
1995, to the present). Were patients who were awaiting heart
transplantation offered left ventricular assist devices when
they became unstable? 
Dr Etoch. Absolutely. We have available the Thoratec,
ABIOMED, and Novacor left ventricular assist devices and
are aggressive in using left ventricular assist devices as a
bridge to transplantation.
Dr Gundry. Were these deaths that occurred while await-
ing transplantation sudden deaths at home, or did they occur
in the hospital, or do you know?
Dr Etoch. I do not know the exact numbers, but the major-
ity were sudden deaths at home.
Dr Gundry. Am I correct that despite the Batista procedure
there is really no difference in the waiting list or waiting prob-
ability of surviving for a heart transplantation candidate or a
Batista candidate? Is that essentially what you are saying?
Dr Etoch. There was no difference in 1-year survival in
patients treated with OHT or PLV.
Dr Gundry. Last, I noticed that all of these patients had
typical dilated cardiomyopathy. Do you have any results of
the Batista operation with ischemic ventricles?
Dr Etoch. No. As part of our prospective study of PLV, we
tried to select a group that would be very homogeneous and
be most likely to benefit from the procedure. For that reason,
we specifically did not include patients with ischemic cardio-
myopathy but specifically directed our attention to patients
with IDCM.
Dr Gundry. I am impressed from your Batista results and
a remarkable lack of late arrhythmic deaths. Our cardiologists
have told us that if they were to design the perfect operation
to create re-entrant ventricular tachycardia, they would
design the Batista procedure. In fact all of our late deaths
have been arrhythmic in nature. Many centers now routinely
place an automatic implantable cardioverter defibrillator at
the time of the initial operation for the Batista operation.
Could you tell us the reason for the amazing lack of late
arrhythmias in your series? 
Dr Etoch. That has been a common problem presented by
other centers as well, with ventricular arrhythmias resulting
in a significant number of deaths. Unlike Dr Moreira and you,
we have been very lucky that we have not had, to date, any
sudden deaths attributable to ventricular arrhythmias after the
operation. This is probably related to the fact that, because of
the other data, we have routinely used amiodarone in our
patients after PLV. We have also taken a very aggressive ap-
proach in placing automatic implantable cardioverter defibril-
lators both before and after the operation. 
Dr Gundry. Finally, I noticed from your article and also
from your slides that, despite an overall improvement in func-
tion even at 1 month after the Batista operation, by 6 and 12
months there begins to be a remarkably large increase in the
standard deviation of the functional class in those patients.
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Does this imply that, despite an overall improvement in func-
tional class, there are a large number of patients whose con-
dition has begun to deteriorate, but who are hidden by the
average number?
Dr Etoch. That is our impression as well, and the problem
with this study and recent other series is the short follow-up
period. If you look at our results, 5 of the 16 patients who
underwent PLV, despite initial improvement, experienced
worsening heart failure. For that reason, we concluded that
with longer follow-up this may indeed ultimately prove to be
a “biologic bridge” to transplantation as opposed to an alter-
native to transplantation.
Dr Gundry. Finally, what would you do for a patient who
is going to require some form of intervention to get him to a
heart transplantation? Would you try the Batista operation
first, or would you go directly to an implantable left ventric-
ular assist device?
Dr Etoch. As time has progressed, we have refined our
approach to these patients, and we are currently looking at
other indices that may suggest a better long-term result after
PLV. Specifically, we are looking at the amount of myocardial
fibrosis and myocyte diameter on endomyocardial biopsy and
response with dobutamine echocardiography. We are less
likely to advise patients with little improvement on dobuta-
mine echocardiography, with myocyte diameter greater than
30 mm, and with significant fibrosis to undergo PLV. We cur-
rently consider patients who have improvement of left ven-
tricular function on dobutamine echocardiography, have
myocyte diameter less than 30 mm, and have minimal myo-
cardial fibrosis to be candidates for PLV.
Dr Marco Zenati (Pittsburgh, Pa). As you are aware, the
question of how to treat regurgitation in the face of partial
ventriculectomy is the subject of much controversy. You also
are aware of Dr Bowling’s results, treating his patients exclu-
sively with mitral valve repair or replacement without ven-
tricular plasty. There are actually preliminary data that show,
in fact, the degree of the residual mitral regurgitation as a pre-
dictor of rehabilitation and follow-up. Would you comment
on how you handle mitral regurgitation?
Dr Etoch. As I mentioned, the mean grade of mitral
regurgitation in our patient group was 3.3. Only 1 patient
did not have mitral regurgitation before the operation; the
remaining 15 patients all had significant mitral regurgita-
tion and were treated at the time of the operation. Thirteen
of these patients underwent mitral valve repair, and 2 of
them underwent mitral valve replacement. Our 1 patient
who did not have mitral regurgitation before the opera-
tion demonstrated similar results and improvements after
the operation, despite requiring no treatment of her mitral
valve.
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